Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-02-06 Director's Dealing
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于公司董事何勤先生减持股份计划的实施进展及终止本次减持计划的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress and termination of a share reduction plan by a company director (何勤先生) of 昆药集团股份有限公司. It details the director's shareholding, the planned reduction, the fact that no shares were sold, and the decision to terminate the plan. This is a report of a personal share transaction by a company director, which fits the definition of Director's Dealing (DIRS). The document is short and focused solely on this insider transaction, with no financial statements or other report content.
2018-02-06 Chinese
独立董事关于聘任公司总裁的独立意见
Board/Management Information Classification · 95% confidence The document is a formal independent opinion from the independent directors regarding the appointment of a company president. It discusses the qualifications, legal compliance, and approval of the appointment. There is no financial data, no report attached or referenced, and no mention of a meeting or voting results. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2018-01-30 Chinese
八届四十七次董事会决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of a board resolution regarding the appointment of a new company president. It includes details about the voting results and the nominee's background. There is no financial data, no mention of annual or quarterly reports, and no indication of a report being attached or published. The content fits the category of Board/Management Information, as it concerns changes in senior management.
2018-01-30 Chinese
2018年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2018 First Extraordinary General Meeting" of KPC Pharmaceuticals, Inc. It contains detailed meeting agenda, voting procedures, and two specific proposals for shareholder approval: amendment of the company articles of association and approval of a loan to a related company. The content is focused on the meeting materials provided to shareholders for the Extraordinary General Meeting (EGM), including explanations of proposals and voting methods. There are no financial statements or audit opinions present, nor is this a transcript or a report of voting results. The document is not an announcement of a report publication but the actual meeting materials. Therefore, this fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings).
2018-01-30 Chinese
关于获得注射用KPCXM18药品临床批件的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the receipt of a clinical trial approval for a new drug (Injection KPCXM18) from the National Medical Products Administration (China's drug regulatory authority). It details the drug's clinical trial approval, research background, and risk warnings related to drug development. The document is a regulatory announcement about a clinical trial approval and does not contain financial statements, earnings data, or detailed management discussion. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a certification, voting result, or management change announcement. Given the nature of the content and the absence of financial data, this fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2018-01-29 Chinese
关于投资杭州巢生股权投资基金合伙企业（有限合伙）的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding its investment in a private equity fund (Hangzhou Chaoshen Equity Investment Fund Partnership). It details the investment amount, fund management, investment strategy, risk analysis, and impact on the company. The document is a formal announcement of a capital investment transaction by the company, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial results but rather describes a financing/investment activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3835 characters, which is consistent with an announcement rather than a full report.
2018-01-24 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.